Key result
DOX-loaded CuZC reduces A549 cancer cell viability by ~44% vs free doxorubicin.
Why the study?
Does DOX-loaded CuZC improve cytotoxicity against A549 cancer cells compared to free DOX?
Does DOX-loaded CuZC improve cytotoxicity against A549 cancer cells compared to free DOX?
Absolute Event Rate: 23% vs 41%
CuZC is a promising nanocarrier for pH-responsive doxorubicin delivery and oxidative stress management in cancer therapy.
CuZC nanocarriers merit further preclinical testing for doxorubicin delivery; leaves open clinical translation pending rigorous validation.
This study presents a multifunctional copper-loaded zeolite 4A–chitosan nanocomposite (CuZC) designed for efficient anticancer drug delivery and oxidative stress management. CuZC was synthesized via a controlled co-precipitation and reflux method and characterized using XRD, FE-SEM, EDX, TEM, and BET analyses to confirm its structural, morphological, and compositional features. Doxorubicin (DOX) loading and release were investigated under different pH conditions to mimic physiological and tumor environments. The nanocomposite exhibited an exceptionally high DOX loading efficiency of 98.9% and showed sustained, pH-responsive drug release, with enhanced release at acidic pH (5.4), favorable for tumor targeting. In vitro cytotoxicity evaluated by the MTT assay on A549 cancer cells revealed that DOX-loaded CuZC induced greater cell inhibition compared to free DOX. Additionally, CuZC demonstrated strong antioxidant activity, achieving approximately 90% DPPH radical scavenging. These findings highlight CuZC as a promising nanocarrier with combined drug delivery efficiency, controlled release, and antioxidant potential for cancer therapy.
No takes yet. Share an insight, caveat, or question.
Rakesh et al. (2026) studied Cancer (in vitro A549 cells). Doxorubicin-loaded CuZC nanocomposite vs. Free doxorubicin was evaluated on Cell viability (A549 cells). Doxorubicin-loaded copper-zeolite-chitosan nanocomposite (CuZC) induced greater cytotoxicity in A549 cancer cells (23% cell viability) compared to free doxorubicin (41% cell viability).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: